Data Insights
                                    By  Company Name
                                
                                No Filter Selected
                                    By  Disease Name
                                
                                No Filter Selected
                                    By  Drug Name
                                
                                No Filter Selected
                                    By Themes
                                
                                No Filter Selected
                                    Showing 2 results out of 2                                
                                
                                                Data Insights
                                                
                                        Risk adjusted net present value: What is the current valuation of BridgeBio Pharma's Ribitol?
Ribitol is a small molecule commercialized by BridgeBio Pharma, with a leading Phase III program in Limb-Girdle Muscular Dystrophy. According...
                                                Data Insights
                                                
                                        Risk adjusted net present value: What is the current valuation of BridgeBio Pharma's Ribitol?
Ribitol is a small molecule commercialized by BridgeBio Pharma, with a leading Phase III program in Limb-Girdle Muscular Dystrophy. According...